Exploration of germline variants responsible for adverse events of crizotinib in anaplastic lymphoma kinase-positive non-small cell lung cancer by target-gene panel sequencing-Reference-Cited by-同舟云学术

Exploration of germline variants responsible for adverse events of crizotinib in anaplastic lymphoma kinase-positive non-small cell lung cancer by target-gene panel sequencing

Published:2019-02 Issue: Volume:128 Page:20-25
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Mizugaki Hidenori,Hamada Akinobu,Shibata Tatsuhiro,Hosoda Fumie,Nakamura Hiromi,Okuma Yusuke^ORCID,Shukuya Takehito,Umemura Shigeki,Horiike Atsushi^ORCID,Fukui Tomoya^ORCID,Kogure Yoshihito^ORCID,Daga Haruko,Urata Yoshiko,Yamada Kazuhiko^ORCID,Saeki Sho,Fujisaka Yasuhito,Nakamura Yukiko,Sato Mitsuo^ORCID,Yoshida Tatsuya,Hotta Takamasa,Oizumi Satoshi,Fujiwara Yasuhiro,Ohe Yuichiro,Fujiwara Yutaka^ORCID

Funder

JSPS KAKENHI

Japan Research Foundation for Clinical Pharmacology

Accelerating Regulatory Science Initiative, Ministry of Health, Labour and Welfare, Japan

National Cancer Center Development Fund

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference28 articles.

1. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer;Soda;Nature,2007

2. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer;Rikova;Cell,2007